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Aims: Maternal antithyroid drug (ATD) use during pregnancy has been associated
with an increased risk of birth defects in offspring. Uncertainty remains on the size of
this risk and how it compares to untreated hyperthyroidism due to methodological
limitations of previous studies.
Methods: Systematic review of MEDLINE and EMBASE identifying observational
studies examining ATD use during pregnancy and risk of birth defects by 28 August
2020. Data were extracted on study characteristics, effect estimates and comparator
groups. Adjusted effect estimates were pooled using a random-effects generic
inverse variance method and absolute risk calculated.
Results: Seven cohort studies and 1 case–control study involving 6 212 322 preg-
nancies and 388 976 birth defects were identified reporting regression effect esti-
mates. Compared to an unexposed population comparison, the association between
ATD use during pregnancy and birth defects in offspring was: adjusted risk ratio
(aRR) 1.16 95% confidence interval (CI) 1.08–1.25 for propylthiouracil (PTU); aRR
1.28 95%CI 1.06–1.54 for methimazole/carbimazole (MMI/CMZ); aRR 1.51, 95%CI
1.16–1.97 for both MMI/CMZ and PTU; and aRR 1.15 95%CI 1.02–1.29 for
untreated hyperthyroidism. The excess risk of any and major birth defects per 1000,
respectively, was: 10.2 and 1.3 for PTU; 17.8 and 2.3 for MMI/CMZ; 32.5 and 4.1
for both MMI/CMZ and PTU; and 9.6 and 1.2 for untreated hyperthyroidism.
Conclusions: When appropriately analysed the risk of birth defects associated with
ATD use in pregnancy is attenuated. Although still elevated, the risk of birth defects
is smallest with PTU compared to MMI/CMZ and may be similar to that of untreated
hyperthyroidism.
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1 | INTRODUCTION
Hyperthyroidism affects between 0.1 and 0.4% of pregnancies and
left untreated, may have detrimental maternal and foetal conse-
quences including increasing the risk of preeclampsia, intrauterine
growth restriction, preterm birth and maternal heart failure.1–3 The
most common cause of hyperthyroidism in young women is Grave's
disease, which results from stimulation of the thyroid by thyrotrophin
receptor stimulating antibodies. This results in elevated free thyroxine
(T4) and/or triiodothyronine (T3) with low thyroid-stimulating hor-
mone (TSH), and typically requires treatment.4 In contrast, gestational
transient hyperthyroidism resulting from thyroid gland stimulation by
the human chorionic gonadotrophin hormone often requires no
treatment.
Clinical guidelines recommending treatment of hyperthyroidism
during pregnancy parallels that of nonpregnant women with use of
antithyroid drugs (ATDs).5,6 Commonly prescribed drugs for the
management of hyperthyroidism in pregnancy are methimazole/
carbimazole (MMI/CMZ) and propylthiouracil (PTU) that are con-
sidered equally effective. Both ATDs can cross the human placenta
and has resulted in uncertainty about the risk of birth defects. PTU
is the preferred ATD during the first trimester of pregnancy due
to rare safety concerns surrounding the possible teratogenic
effects of MMI/CMZ.7 The reported MMI/CMZ embryofoetopathy
include aplasia cutis congenita (absence of a portion of skin, often
localised on the head), craniofacial birth defects (choanal atresia;
facial dysmorphism), defects of the abdominal wall and gastrointes-
tinal tract (exomphalos, oesophageal atresia, omphalomesenteric
duct anomaly), and ventricular septal defect.8 Consequently, in the
first trimester of pregnancy clinical guidelines recommend switching
from MMI/CMZ to PTU therapy in women with unplanned preg-
nancies and then using MMI/CMZ thereafter due to concerns of
PTU hepatotoxicity.9 The role of PTU during pregnancy has been
re-examined following reports of birth defects. These safety
concerns recently led to updated warnings from the European
Medicines Agency on the use of PTU and MMI/CMZ during
pregnancy.10,11
Two meta-analyses were recently published reporting that use
of MMI/CMZ and PTU during pregnancy were associated with an
increased risk of birth defects.12,13 These meta-analyses used the
number of cases and the number of people in the sampled popula-
tion from observational studies to calculate pooled effect estimates
for exposure to MMI/CMZ and exposure to PTU during pregnancy.
By analysing data from observational studies as if they were trials,
such estimates represent crude associations that are likely to be
confounded.14 Heterogeneity between studies may also occur
through the use of different study designs and further information
from other types of comparator or reference groups may aid deci-
sion making. The aim of this study was to examine the association
between the use of MMI/CMZ or PTU during pregnancy and the
risk of birth defects in offspring, through systematic review and
meta-analysis of data using more appropriate methods to support
causal inference.
2 | METHODS
A review of MEDLINE and EMBASE was conducted using a
prespecified search strategy to identify all observational studies
(cohort, case–control and sibling studies) assessing the risk of birth
defects associated with the use of PTU or MMI/CMZ during preg-
nancy, published on or before 28 August 2020. The search strategy is
reported in the online supplementary material. Titles and abstracts
were screened, and full texts of relevant articles assessed for eligibility
by 2 authors. Only English language publications and published data
were included as we had no resources to translate articles. The
systematic review was registered on the EU Register of
Post-Authorisation Studies (EUPAS30990) and reported according to
PRISMA (Preferred Reporting Items for Systematic Reviews).15
2.1 | Inclusion and exclusion criteria
First, studies were included if they reported regression effect esti-
mates, and the type of confounding adjustment and study design
were described. Of these, meta-analysis was performed using only
those studies reporting adjusted effect estimates for the association
between ATDs and birth defects. Second, for estimating absolute risk
difference (excess number of birth defects per 1000 pregnancies)
studies were included if they reported birth defect rates from ATD
exposed and from an untreated general population comparison group.
Studies reporting birth defect rates among other selected populations
of women were excluded.
What is already known about this subject
• Maternal antithyroid drug use during pregnancy has been
associated with an increased risk of birth defects in
offspring.
• Uncertainty remains on the size of this risk and how it
compares to untreated hyperthyroidism due to methodo-
logical limitations of previous studies, including meta-
analyses.
What this study adds
• Previously conducted meta-analyses have over-estimated
the risk of birth defects associated with antithyroid drug
use during pregnancy due to bias.
• Propylthiouracil use during pregnancy is associated with
a smaller risk of birth defects compared to methimazole/
carbimazole and may be similar in size as that observed
with untreated hyperthyroidism.
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2.2 | Risk of bias
Methodological quality and risk of bias were evaluated for each study
using the ROBINS-I tool.16 This tool is designed to assess the
strengths and weaknesses of nonrandomised studies on the effects of
interventions in relation to their risk of bias. The ROBINS-I tool covers
7 distinct domains, through which bias could be introduced: con-
founding, selection of participants into the study, classification of
interventions, deviations due to intended interventions, missing data,
measurement of outcome measures and selection of the reported
result.
2.3 | Data extraction
We extracted data from eligible studies for the following characteris-
tics: study design; study population; sample size; exposure definition;
type of comparator or reference group reported; and the accuracy
and completeness of information on confounders. For each compari-
son, crude and adjusted regression effect estimates (odds ratios, haz-
ard ratios or rate ratios) were identified with corresponding 95%
confidence intervals (CIs). The outcome of interest were the risk of
birth defects in children following MMI/CMZ exposure, PTU expo-
sure, and both MMI/CMZ and PTU exposure during pregnancy.
2.4 | Comparator groups and alternative study
designs
Confounding by indication may occur when the underlying indication
is associated with the outcome being studied. Using different compar-
ator or reference groups may help to circumvent or minimise this
potential confounding.17,18 To examine the effect of different com-
parator groups on such confounding, regression effect estimates for
the following prespecified comparator groups were sought:
i. maternal exposure during pregnancy vs. all unexposed women
(also called the unexposed population comparison group, and
referred to as the classical comparison);
ii. maternal exposure during the prepregnancy period (discontinuers)
vs. all unexposed women (this exposure may act as a negative
control and should theoretically be noncausal);
iii. maternal exposure during pregnancy vs. an unexposed disease
comparison group that may reduce confounding by indication or
severity (in this context the direct effect of hyperthyroidism);
iv. siblings analyses with discordant prenatal medication exposure
(this study design accounts for all time-fixed within-family
confounding);
v. paternal exposure during pregnancy vs. all unexposed women
(this exposure may act as a negative control and should theoreti-
cally be noncausal); and
vi. an unexposed disease comparison group vs. all unexposed
women (testing for confounding by indication).17,18
2.5 | Analysis
The characteristics of each study and method of confounding adjust-
ment for studies reporting regression effect estimates were first
described. The number of cases and total population from each study
were then used to replicate the meta-analytical approach used by Li
et al., which used a Mantel–Haenzel fixed-effect model.14 Adjusted
effect estimates from all identified studies were then extracted, trans-
formed on the natural log scale and pooled using the generic inverse
variance method of analysis. Random-effects models were generated
for each type of exposure and comparator group separately. When >1
study used the same data source, the largest study was initially
selected with sensitivity analysis substituting this with other studies
from the same data source. We also substituted effect estimates for
studies that reported data for both any birth defect and for a sub-
group related to CMZ/MMI. Furthermore, we performed a leave-
1-out comparison with 2 studies that reported exposure as during
pregnancy as opposed to all other studies that specifically measured
first trimester exposure. Odds ratios from case–control studies and
hazard ratios from cohort studies were combined because they closely
approximate each other.19,20 For reporting, pooled effect estimates
are subsequently referred to as risk ratios (RR) throughout. Publication
bias was assessed by testing for funnel-plot asymmetry using the
Egger test. Analyses were conducted in Review Manager 5.3
(Copenhagen: The Nordic Cochrane Centre, The Cochrane Collabora-
tion, 2014).
To estimate absolute risk differences, the rate of birth defects
(any, major) from general unexposed population estimates was first
extracted from each study and presented as the rate per 1000 live
births. The pooled adjusted effect estimates from the meta-analysis
were then used to calculate the absolute risk of birth defects (any,
major) per 1000 live births for each exposure group of interest. The
absolute risk difference was then calculated by subtracting the birth
defect rate (any, major) in the unexposed general population from
each exposure group.
3 | RESULTS
The systematic review identified 15 potentially relevant studies.
We included 8 studies reporting regression estimates to describe
the types of confounding adjustment and study design, and
excluded 7 studies without regression estimates (Figure 1). The
characteristics of these studies are presented in Table 1 (included
studies) and Table S1 (excluded studies).21–35 Of the included stud-
ies reporting effect estimates, 7 were cohort studies (involving
6 195 342 pregnancies and 388 864 birth defects)21–26,28 and
1 was a case–control study (involving 16 980 pregnancies and
112 birth defects).27 Two of these studies were conducted using
the same overlapping populations from Denmark.21,24 Of the com-
parator groups reported, 5 studies reported adjusted effect esti-
mates for the risk of birth defects associated with use of
MMI/CMZ during pregnancy vs. an unexposed population
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comparison group (the classical comparison), and 1 study compared
MMI/CMZ use to an unexposed disease comparison group
(Table S2). The corresponding number of studies for PTU were
5 using a classical comparison and 2 using a disease comparison
group respectively. For use of both MMI/CMZ and PTU during
pregnancy (i.e. switching), 3 studies reported adjusted effect esti-
mates for the classical comparison. No studies were identified that
undertook a sibling study design, examined prepregnancy exposure
or paternal exposure. However, 1 study used a comparator con-
sisting of either prepregnancy and postpregnancy exposure.
3.1 | Meta-analysis
The meta-analytical approach used by Li et al. was first replicated
using the number of reported cases and total population with a
Mantel–Haenzel fixed-effect model. When analysed in this way,
maternal MMI/CMZ exposure and PTU exposure during pregnancy
was associated with a significantly increased risk of birth defects in
offspring compared to the classical reference group of all unexposed
women (RR 1.20 95%CI 1.02–1.42 for PTU; RR 1.64 95%CI
1.39–1.92 for MMI/CMZ; RR 1.83 95%CI 1.30–2.56 for MMI/CMZ
and PTU use, Figure S1).
When only adjusted effect estimates were pooled using the
inverse variance method of analysis, maternal use of MMI/CMZ dur-
ing pregnancy was associated with a smaller but still significantly
increased risk of birth defects compared to all unexposed women
(random-effects adjusted RR [RaRR] 1.28 95%CI 1.06–1.54, Figure 2).
This was similarly the case for use of PTU (RaRR 1.16 95%CI
1.08–1.25) and exposure to both MMI/CMZ and PTU during preg-
nancy (RaRR 1.51 95%CI 1.16–1.97).
The risk of birth defects among unexposed women with hyper-
thyroidism compared to unexposed women without hyperthyroidism
was also significantly elevated (RaRR 1.15 95%CI 1.02–1.29,
Figure 3). When PTU exposure was compared to unexposed women
with hyperthyroidism reported in 2 studies, PTU exposure during
pregnancy was not associated with an increased risk of birth defects
(RaRR 0.72 95%CI 0.47–1.11, Figure 3). In contrast, only 1 study
reported this comparison for MMI/CMZ that was significantly ele-
vated (RR 2.28, 95%CI 1.54–3.33).
F IGURE 1 PRISMA (Preferred Reporting
Items for Systematic Reviews) flow diagram for
study selection process for the meta-analysis
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3.2 | Sensitivity analyses
Two studies were conducted using the same data source from
Denmark but covering different time periods.21,24 When Andersen
et al. (2019)21 was substituted for Andersen et al. (2013),24 pooled
effect estimates for MMI/CMZ exposure and PTU exposure were
RaRR 1.28 (95%CI 0.96–1.71) and RaRR 1.17 (95%CI 1.09–1.26)
respectively. Two studies also reported effect estimates for subgroups
of birth defects and exposure to CMZ/MMI and 1 study for PTU
(Table S3).21,23 When effect estimates for subgroups of birth defects
were substituted, pooled effect estimates for exposure to MMI/CMZ
was RaRR 1.37 (95%CI 0.98–1.91) and RaRR 1.17 (95%CI 1.09–1.26)
for PTU (Figure S2). The results of the leave-1-out analysis for 2 stud-
ies measuring ATD exposure during pregnancy rather than specifically
as first trimester exposure were similar to the main results (Table S4).
3.3 | Absolute risk
For calculating overall absolute risk differences, we included 4 stud-
ies for any birth defects and 3 studies for major birth defects
(Table 2). The overall rate of birth defects in unexposed women was
63.7 per 1000 live births for any birth defect and 8.2 per 1000 for
major birth defects (Table 2). The absolute risk difference for any
birth defect compared to the unexposed population comparison
group per 1000 live births was estimated at: 9.6 in women with
unexposed hyperthyroidism; 10.2 in women treated with PTU; 17.8
in women treated with MMI/CMZ; and 32.5 in women treated with
both MMI/CMZ and PTU during pregnancy (Table 2). Corresponding
numbers for major birth defects per 1000 live births were 1.2, 1.3,
2.3 and 4.1.
3.4 | Assessment of confounding factors and risk
of bias
Of the 8 studies, 6 adjusted for maternal age, and 3 for each of the
following: the infant's sex; year of birth; parity; and pregnancy type
(Table S5). Adjustment for maternal physical history and smoking sta-
tus occurred in 3 and 2 studies respectively. Adjustment of maternal
physical history consisted mainly of metabolic conditions including
diabetes and hyperlipidaemia. No studies adjusted for alcohol use dur-
ing pregnancy and only 1 study adjusted for any other type of medica-
tion use during pregnancy, namely antiepileptic use.
For the classical comparison using all unexposed women, the risk
of bias varied according to the domain studied and was influenced by
variation in the type of confounding adjustment undertaken and
uncertainty around exposure and outcome ascertainment bias
(Table S6). The Egger test for MMI/CMZ exposed vs. all unexposed
women (P = .020), PTU exposed vs. all unexposed women (P = .005)
and PTU and MMI/CMZ exposed vs. all unexposed women (P = .027)
were statistically significant for funnel plot asymmetry, although the
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4 | DISCUSSION
Meta-analysis is a powerful tool that combines estimates from multi-
ple studies to improve power and precision, whilst allowing questions
to be answered that are limited by individual studies. Meta-analysing
data from observational studies examining the risk of ATD exposure
during pregnancy as if they were trials may overestimate risk, which
attenuates when more appropriate methods are used. However,
observed associations between birth defects and exposure to PTU
and/or MMI/CMZ were still elevated. Pooled effect estimates for
F IGURE 2 Association between
maternal antithyroid drug exposure
during pregnancy and risk of congenital
anomalies in offspring compared to
untreated women without
hyperthyroidism when analysing adjusted
effect estimates. CMZ = carbimazole;
MMI = methimazole;
PTU = propylthiouracil
F IGURE 3 Associations between the risk of congenital anomalies in offspring of nonmedicated women with hyperthyroidism compared to all
nonmedicated women without hyperthyroidism (A) and propylthiouracil (PTU) exposure during pregnancy compared to all nonmedicated women
with hyperthyroidism (B)
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women using PTU and unexposed women with hyperthyroidism were
similar in size, whilst the highest risk estimates were observed in the
groups switching between MMI/CMZ and PTU.
PTU is typically considered the safer option when hyperthyroid-
ism requires treatment during the first trimester of pregnancy. How-
ever, safety concerns surrounding PTU exposure and the risk of
hepatic toxicity and birth defects have emerged leading to regulatory
updates to the product information in 2011 and 2019
respectively.9–11 Our findings for PTU exposure during pregnancy are
reassuring as they suggest that it does not increase the risk of birth
defects beyond that of the underlying maternal disease, but poten-
tially has the advantage of reducing maternal morbidity associated
with untreated hyperthyroidism according to previous research.3
The highest risk of birth defects was associated with use of
both MMI/CMZ and PTU during pregnancy that corresponds to
women who switch from 1 product to the other. The effects of
switching can be difficult to interpret with these data as the order
of switching was not always specified. However, in the majority of
instances, switches appeared to be appropriate as most changed
from MMI/CMZ to PTU during the first trimester of pregnancy.
Given current guideline recommendations, this could represent a
group more likely to include women with unplanned pregnancies
that may differ in terms of lifestyle and early folic acid use for
example. Whilst we cannot exclude the possibility that confounding
by the severity of hyperthyroidism plays a role we would expect
treated women to become euthyroid as their disease is controlled
with ATD medication.
Our analysis demonstrates that using adjusted effect estimates is
important to appropriately account for measured confounding factors
and that risk estimates from meta-analyses based upon crude num-
bers may be of limited value for clinical and regulatory decision mak-
ing. We recommend avoiding this method of meta-analysis for
nonrandomised studies when adjusted effect estimates from observa-
tional studies are available. This is particularly important when such
estimates are used to calculate absolute risk. In this regard, individual
observational studies should be properly designed and conducted to
provide the appropriate primary data, including being adequately
powered to reduce the risk of a type-II error.
TABLE 2 Estimated excess number of birth defects per 1000 live births associated with methimazole/carbimazole (MMI/CMZ) exposure,
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Denmark 1 159 181 67.1 10.1 10.7 18.8 34.2
Seo
201822
Korea 2 872 109 59.4 8.9 9.5 16.8 30.3
Andersen
201723
Sweden 682 343 80.4 12.1 12.9 22.5 41.0
Andersen
201324
Denmark 811 730 56.7 8.5 9.1 15.9 28.9
Korelitz
201325
USA 634 858 58.8 8.8 9.4 16.5 30.0





Taiwan 14 150 6.5 1.0 1.0 1.8 3.3
Lian
200532
China 22 765 9.3 1.4 1.5 2.6 4.7
Momotani
198435
Japan 350 2.9 0.4 0.5 0.8 1.5
Overall 40 095 8.2 1.2 1.3 2.3 4.1
*Overall rate for any birth defect calculated using Andersen 201921 and excluding Andersen 201324 due to the overlapping population.
**Yoshihara 2012,26 Rosenfeld 2009,28 Hawken 2016,29 Lo 2015,30 Clementi 2010,31 Gianantonio 200133 and Wing 199434 were excluded from the
calculation of overall rate estimates and absolute risk differences as they did not report baseline birth defect rates from an unexposed general population
comparison group. Exposure not only restricted to the first trimester (Korelitz 2013, Chen 2011).
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This study has several potential limitations. First, although
accounting for confounding attenuated the observed associations, the
included studies were heterogeneous in their approach to con-
founding adjustment suggesting that residual confounding remains
possible. First trimester exposure was specifically evaluated in most
but not all studies. However, the leave-1-out analysis produced similar
results suggesting that these estimates are relevant to first trimester
exposure. Studies were also heterogeneous in the outcome definition
with some studies measuring any birth defects (also minor) whilst
other focused on major birth defects. The baseline birth defect rate
was as high as 8% in 1 study, probably due to inclusion of neonatal
anomalies that according to the EuroCat classification system are
minor anomalies for exclusion.23,36 Heterogeneity may have also
resulted from studies using different types of data source. Other fea-
tures that could have affected the risk estimates include not excluding
offspring with birth defects due to genetic disorders. This may intro-
duce bias if women with hyperthyroidism/Graves disease have an
increased risk of having children with birth defects of genetic origin.37
Moreover, ascertainment bias related to the outcome is expected as
clinicians may scrutinize children of women with hyperthyroidism to a
greater extent than children of healthy women, especially after the
signals of ATD teratogenicity. Although this could have a larger effect
on studies with shorter follow-up to detect outcomes we observed no
obvious impact of this with the included studies. For these reasons, it
is important to consider using an unexposed disease comparison
group as an alternative comparator to better infer causality.17,18 Nota-
bly no sibling study designs have been reported despite the potential
advantage of controlling for shared familial confounding by design.
The majority of included studies assessed only birth defects in live
births, which will miss defects due to elective termination, miscar-
riages or stillbirths. Conditioning on live births may give rise to collider
bias if both exposure and outcome are associated with survival.38
Despite the advantages of having an unexposed disease comparison
group, this approach may not account for differences in the severity
or type of hyperthyroidism. It is likely that transient gestational hyper-
thyroidism may represent a significant proportion of untreated cases
whereas Graves disease will probably be treated. Although we dem-
onstrated comparable risk from PTU exposure and untreated hyper-
thyroidism, the overall number of studies was small and further
observational studies may be useful, including those that explore the
relationships between different comparator groups and study designs.
We also cannot exclude the possibility of publication bias. Finally, this
study examines birth defects as a composite outcome and data may
not be generalizable to subtypes of birth defects such as MMI
embryofoetopathy. However, whilst MMI/CMZ may be associated
with a larger risk of birth defects not all studies consistently reported
an elevated risk demonstrating that some uncertainty about this asso-
ciation remains. For example, in a large study from Sweden there were
no cases of aplasia cutis and choanal or oesophageal atresia that have
described as being the MMI embryopathy.23 The only study that was
sufficiently powered to assess this birth defect pattern, however,
found 5 additional cases of MMI embryopathy per 10 000 after first
trimester exposures to ATDs compared to nonexposed (0.12 vs.
0.07%).22 This was also the only study to report a dose–response rela-
tionship and observed larger risk estimates for congenital anomalies
with high cumulative doses of CBZ/MMI but not with PTU.
Future studies should evaluate the association between ATD and
birth defects using comparable definitions of exposure and outcomes
aligned with current recommendations and standards.36,39 Estimates
should be reported separately for CMZ/MMI and PTU rather than by
ATD group that is still evaluated.40 Major groups of birth defects
should also be investigated separately rather than any birth defect,
and minor birth defects should preferably be studied as part of malfor-
mation patterns. Future studies should also consider incorporating
additional types of comparators or reference groups in their designs
(such as untreated hyperthyroidism or prepregnancy ATD exposure),
ensure data sources have reasonable power to study the birth defects
of interest, and consider the use of sibling study designs to address
familial confounding. Techniques to quantify residual confounding for
example by severity of maternal hyperthyroidism and unmeasured
confounders could also be useful.18
Assuming MMI/CMZ and PTU are equally effective, our findings
suggest that PTU use is the safer option in terms of the risk of birth
defects in offspring, and that untreated hyperthyroidism may also
carry a risk. This suggests that the net benefit of managing hyperthy-
roidism during the first trimester of pregnancy is in favour of using
PTU when clinically indicated. However, such use must also be bal-
anced against other potential risks with PTU such as hepatoxicity and
the limitation of current observational studies.
5 | CONCLUSION
Previous meta-analyses examining the risk of maternal ATD use dur-
ing pregnancy overestimate the risk of birth defects in offspring.
When appropriately analysed this risk is attenuated. Although still ele-
vated, the risk of birth defects is smallest with use of PTU during
pregnancy.
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